Given the success of the previous collection, Molecular Biomarkers of Cardiometabolic Disease, and the new advances in the field, we are pleased to announce the launch of Volume II.

Cardiometabolic disease (CMD) is a critical area of research due to its status as the leading cause of mortality worldwide, responsible for one-third of all global deaths, with a significant impact on middle- and low-income countries. The current challenge in CMD research lies in the limited predictive capabilities of classical risk factors, necessitating the development of more accurate molecular predictors. Recent studies have highlighted the potential of various circulating biomarkers, such as C-reactive protein (CRP), leptin, and adiponectin, in assessing CMD risk. Furthermore, emerging evidence suggests the involvement of novel biomarkers, including cytokines, metabolites, apelin, microRNAs, inflammasome molecules, and cardiac fibrosis markers. Despite these advancements, there remains a gap in large-scale meta-analyses to confirm their roles in CMD diagnosis and prognosis. Addressing this gap requires innovative approaches, such as integrating multi-omics analyses, to create a comprehensive molecular framework for CMD and identify effective biomarkers.

This Research Topic aims to explore novel and promising research and clinical trends in the identification, characterization, assessment, and application of molecular biomarkers for CMD. The primary objective is to encourage the discovery and evaluation of new biomarkers that can enhance risk assessment, screening, diagnosis, and prognosis of CMD. By leveraging high-throughput methodologies, the research seeks to critically evaluate the roles of genetic and epigenetic factors in CMD-associated complications, such as insulin resistance, type 2 diabetes, and cardiovascular disease. The goal is to systematically assess their potential applications as molecular biomarkers, ultimately improving CMD management and outcomes.

To gather further insights in the identification and application of molecular biomarkers for CMD, we welcome articles addressing, but not limited to, the following themes:

• Identification and experimental validation of novel molecular biomarkers of CMD

• Investigation of novel genetic, epigenetic, and biochemical biomarkers of CMD

• Experimental and clinical evaluation of miRNAs as potential epigenetic biomarkers of CMD

• Use of combinations of biomarkers and panels of biomarkers for CMD risk prediction, diagnosis, and prognosis

• Machine learning as a tool for the identification of potential novel molecular biomarkers of CMD

We are interested in publishing reviews and research articles that contribute to this evolving field.

Submit your idea

Impact

Frontiers in Endocrinology

Submit your idea

Impact